Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock
The meteoric rise of the semaglutide weight-loss therapy market has encountered an unexpected slowdown, leaving distributors with significant inventory surpluses. After a massive surge following patent expirations, the sudden cooling of demand has left the trade channel grappling with an estimated ₹100 crore in excess stock.
From Rapid Surge to Inventory Overhang
The Indian obesity therapy market, valued at approximately ₹2,000 crore, experienced a period of explosive growth in April. Following the patent expiry of semaglutide on March 20, the market saw a flood of cheaper generic alternatives from major pharmaceutical players, including Sun Pharma, Dr. Reddy's, and Torrent Pharmaceuticals. This influx led to a massive 50% month-on-month (m-o-m) value surge and an 88% jump in volumes in April alone.
However, the momentum shifted abruptly in May. According to data from market research firm Pharmarack, month-on-month value growth slowed to just 6%, while unit growth decelerated to 12%. This slowdown has created a significant inventory overhang. Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), noted that stockists and wholesalers are currently holding 50–60 days of inventory, significantly higher than the industry standard of 30–45 days.
Impact on the Pharmaceutical Supply Chain
The accumulation of excess stock has triggered a defensive reaction across the pharmaceutical supply chain. To prevent further losses, stockists and wholesalers have halted fresh procurement from manufacturers until existing inventories are liquidated. With the estimated excess stock in the trade channel valued at nearly ₹100 crore, the pause in orders could create short-term revenue challenges for the generic manufacturers who recently entered the fray.
While semaglutide faces this inventory crunch, other therapies in the GLP-1 (glucagon-like peptide-1) receptor agonist class continue to show resilience. Eli Lilly’s Mounjaro (tirzepatide), used for managing type 2 diabetes and obesity, remained the top-selling therapy in the pharma market in May, with sales rising 12% to reach ₹136 crore.
Regulatory Guidelines and Market Moderation
Industry experts suggest that the moderation in semaglutide sales may not be purely a matter of supply and demand, but also a result of regulatory tightening. In April, government advisories introduced stricter prescribing restrictions for GLP-1 therapies. These new guidelines stipulate that these specific medicines should only be prescribed by qualified specialists.
This regulatory shift, combined with the initial "rush" to capitalize on generic availability, appears to have led to an overestimation of immediate demand. As the organized pharma retail market continues to grow—up 11% in May, largely driven by chronic therapies—the semaglutide segment must now navigate a period of stabilization and stock liquidation.
Key Takeaways
- Inventory Surplus: The semaglutide trade channel is currently sitting on an estimated ₹100 crore of excess stock, with distributors holding up to 60 days of inventory.
- Growth Slowdown: After a massive 50% value surge in April, May saw growth plummet to just 6% month-on-month.
- Regulatory Impact: Stricter government guidelines requiring specialists to prescribe GLP-1 therapies are believed to be contributing to the cooling demand.